Newbridge Financial Services Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Newbridge Financial Services Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18	Closed	-$369	–	1296
2023 Q3	$369	Hold	18	–	–	﹤0.01%	1218
2023 Q2	$358	Hold	18	–	–	﹤0.01%	1271
2023 Q1	$308	Hold	18	–	–	﹤0.01%	1340
2022 Q4	$352	Hold	18	–	–	﹤0.01%	1370
2022 Q3	$0	Hold	18	–	–	﹤0.01%	1460
2022 Q2	$0	Hold	18	–	–	﹤0.01%	1489
2022 Q1	$0	Hold	18	–	–	﹤0.01%	1536
2021 Q4	$0	Hold	18	–	–	﹤0.01%	1517
2021 Q3	$1K	Hold	18	–	–	﹤0.01%	1299
2021 Q2	$1K	Hold	18	–	–	﹤0.01%	1384
2021 Q1	$1K	Buy	+18	New	+$988	﹤0.01%	1312

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Newbridge Financial Services Group's RCKT Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Rocket Pharmaceuticals (RCKT) in Q4 2023, closing a stake of 18 shares — an estimated $369 sold.

Newbridge Financial Services Group first reported a position in RCKT in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q3 2021. 194 funds tracked by Wall St. Rank hold RCKT as of Q4 2023.

Newbridge Financial Services Group reported no remaining Rocket Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 18 Rocket Pharmaceuticals shares in Q4 2023, an estimated $369.
Newbridge Financial Services Group first reported a position in Rocket Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Newbridge Financial Services Group's Rocket Pharmaceuticals position peaked at $1K in Q3 2021.
194 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.